Nurse Practitioner Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Lacee Meyer

Geriatric Medicine Bellevue, WA Nurse Practitioner

NPI 1689448870 CMS profile 11527032

50 116Th Ave Se, Suit 111, Bellevue, WA 98004

Open in the dashboard

General payments

$2,942

81 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lacee Meyer of Bellevue, WA is reported in the CMS Open Payments database as having received $2,942 across 81 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Geriatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,101 34
2024 General $1,459 44
2023 General $382 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lacee Meyer
  • Geriatric Medicine median
  • Middle half of Geriatric Medicine
  • National median

In program year 2025, general payments to Lacee Meyer were reported at $1,101. Among 512 Geriatric Medicine profiles paid that year, the median was $120 and the middle half received between $37 and $350.

Show as a table
Year Lacee Meyer Geriatric Medicine median Middle half National median
2019 $0 $96 $28–$339 $163
2020 $0 $99 $28–$262 $114
2021 $0 $94 $27–$318 $132
2022 $0 $103 $34–$338 $149
2023 $382 $109 $39–$320 $160
2024 $1,459 $125 $36–$371 $164
2025 $1,101 $120 $37–$350 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. AbbVie, Inc. $1,482 22 payments
  2. Antares Pharma, Inc. $202 13 payments
  3. Aimmune Therapeutics, Inc. $148 6 payments
  4. Gilead Sciences, Inc. $142 2 payments
  5. Axsome Therapeutics, Inc. $118 1 payment
  6. Pfizer Inc. $92 4 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $90 4 payments
  8. Neuronetics, Inc. $90 4 payments
  9. Lilly USA, LLC $88 4 payments
  10. Novo Nordisk Inc $79 3 payments
  11. Other $411 18 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $2,942 81 payments
Products named General payments · program years 2023–2025
  1. BOTOX $769 10 payments
  2. XYOSTED $202 13 payments
  3. ZENPEP $148 6 payments
  4. CREON $124 5 payments
  5. Yeztugo $122 1 payment
  6. Auvelity $118 1 payment
  7. LINZESS $98 4 payments
  8. XIFAXAN $90 4 payments
  9. Neurostar TMS Therapy System $90 4 payments
  10. ZEPBOUND $88 4 payments
  11. Other $755 33 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

12

Median for Family Medicine: 130

Drug cost

$627

Median for Family Medicine: $5,773

Branded share of claims

100%

Median for Family Medicine: 16%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 12 $627

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 699 Part D prescribers listed as Family Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $385
$385 — —
XYOSTED
  • Antares Pharma, Inc. $187
$187 — —
Auvelity
  • Axsome Therapeutics, Inc. $118
$118 — —
Azstarys
  • Corium, Inc. $53
$53 — —
ZENPEP
  • AIMMUNE THERAPEUTICS, INC. $52
$52 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

81 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Geriatric Medicine in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record